ANG Lifesciences India Analysis

dividend

Pros

Cons

• Unable to evaluate ANG Lifesciences India's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate ANG Lifesciences India's dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• ANG Lifesciences India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• ANG Lifesciences India is profitable, therefore cash runway is not a concern.
• ANG Lifesciences India is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (38.6%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 3.3x debt.
• ANG Lifesciences India's cash and other short term assets cover its long term commitments.
• The level of debt compared to net worth has been reduced over the past 5 years (411.7% vs 61.2% today).
• Interest payments on debt are well covered by earnings (EBIT is 4.3x coverage).

Cons

• ANG Lifesciences India's level of debt (61.2%) compared to net worth is high (greater than 40%).
• High level of physical assets or inventory.

management

Pros

• Rajesh's remuneration is about average for companies of similar size in India.
• The tenure for the ANG Lifesciences India management team is about average.

Cons

• The average tenure for the ANG Lifesciences India board of directors is less than 3 years, this suggests a new board.
• Rajesh's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.

misc

Pros

Cons

• ANG Lifesciences India is not covered by any analysts.
• ANG Lifesciences India's last earnings update was 215 days ago.
• ANG Lifesciences India has significant price volatility in the past 3 months.

past

Pros

• ANG Lifesciences India has delivered over 20% year on year earnings growth in the past 5 years.
• ANG Lifesciences India used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.

Cons

• ANG Lifesciences India's 1-year earnings growth is less than its 5-year average (7.3% vs 34.7%)
• ANG Lifesciences India's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
• ANG Lifesciences India has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
• ANG Lifesciences India's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (7.3% vs 22.7%).

value

Pros

• ANG Lifesciences India is good value based on assets compared to the IN Pharmaceuticals industry average.
• ANG Lifesciences India is good value based on earnings compared to the IN Pharmaceuticals industry average.
• ANG Lifesciences India is good value based on earnings compared to the India market.
• 540694 outperformed the Market in India which returned -14.5% over the past year.

Cons

• ANG Lifesciences India's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• ANG Lifesciences India's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
• 540694 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
• BSE:540694 is down -4.8% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• BSE:540694 is down -4.8% underperforming the market in India which returned 8% over the past month.